Vasko Kramer1,2, Agnete Dyssegaard3, Jonathan Flores4, Cristian Soza-Ried4, Frank Rösch5, Gitte Moos Knudsen3, Horacio Amaral4,6, Matthias M Herth7,8. 1. Center for Nuclear Medicine & PET/CT Positronmed, Providencia, 7501068, Santiago, Chile. vkramer@positronpharma.cl. 2. Positronpharma SA, Providencia, 7500921, Santiago, Chile. vkramer@positronpharma.cl. 3. Center for Integrated Molecular Brain Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. 4. Center for Nuclear Medicine & PET/CT Positronmed, Providencia, 7501068, Santiago, Chile. 5. Institute of Nuclear Chemistry, Johannes Gutenberg-University, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany. 6. Positronpharma SA, Providencia, 7500921, Santiago, Chile. 7. Department of Drug Design and Pharmacology, University of Copenhagen, Jagtvej 160, 2100, Copenhagen, Denmark. matthias.herth@sund.ku.dk. 8. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. matthias.herth@sund.ku.dk.
Abstract
PURPOSE: The serotonin receptor subtype 2A antagonist (5-HT2AR) (R)-[18F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT2ARs. It displays a very similar selectivity profile as [11C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT2AR. As [11C]MDL 100907, (R)-[18F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT2AR binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[18F]MH.MZ PET to image and quantify the 5-HT2AR in the human brain in vivo. METHODS: Nine healthy volunteers underwent (R)-[18F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time-activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[18F]MH.MZ 5-HT2AR binding, and performance of different kinetic modeling approaches. RESULTS: Highest uptake was determined in 5-HT2AR rich regions with a BPND of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[18F]MH.MZ binding conformed to the known distribution of 5-HT2AR and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100-110 min. CONCLUSION: (R)-[18F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT2AR system in humans. In comparison with [11C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[18F]MH.MZ. We believe that (R)-[18F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT2AR system.
PURPOSE: The serotonin receptor subtype 2A antagonist (5-HT2AR) (R)-[18F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT2ARs. It displays a very similar selectivity profile as [11C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT2AR. As [11C]MDL 100907, (R)-[18F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT2AR binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[18F]MH.MZ PET to image and quantify the 5-HT2AR in the human brain in vivo. METHODS: Nine healthy volunteers underwent (R)-[18F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time-activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[18F]MH.MZ 5-HT2AR binding, and performance of different kinetic modeling approaches. RESULTS: Highest uptake was determined in 5-HT2AR rich regions with a BPND of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[18F]MH.MZ binding conformed to the known distribution of 5-HT2AR and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100-110 min. CONCLUSION: (R)-[18F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT2AR system in humans. In comparison with [11C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[18F]MH.MZ. We believe that (R)-[18F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT2AR system.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Matthias M Herth; Fabian Debus; Markus Piel; Mikael Palner; Gitte M Knudsen; Hartmut Lüddens; Frank Rösch Journal: Bioorg Med Chem Lett Date: 2007-12-25 Impact factor: 2.823
Authors: M Talvik-Lotfi; S Nyberg; A L Nordström; H Ito; C Halldin; F Brunner; L Farde Journal: Psychopharmacology (Berl) Date: 2000-03 Impact factor: 4.530
Authors: Lars H Pinborg; Karen H Adams; Claus Svarer; Søren Holm; Steen G Hasselbalch; Steven Haugbøl; Jacob Madsen; Gitte M Knudsen Journal: J Cereb Blood Flow Metab Date: 2003-08 Impact factor: 6.200
Authors: Alexander Hammers; Richard Allom; Matthias J Koepp; Samantha L Free; Ralph Myers; Louis Lemieux; Tejal N Mitchell; David J Brooks; John S Duncan Journal: Hum Brain Mapp Date: 2003-08 Impact factor: 5.038
Authors: Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth Journal: J Neurochem Date: 2021-10-03 Impact factor: 5.546
Authors: Adam J Rosenberg; Yiu-Yin Cheung; Fei Liu; Todd E Peterson; James Silverman; Ciaran M Considine; Daniel O Claassen Journal: J Labelled Comp Radiopharm Date: 2022-05-06 Impact factor: 1.949